- SafeHeal® Closes Oversubscribed €35 Million Series C Equity Financing: Click here to read the press release
- SafeHeal Receives Breakthrough Device designation for Colovac Endoluminal Bypass Sheath: Click here to read the press release
- Chief Executive Officer Chris Richardson to Speak at LSI Emerging Medtech Summit: Click here to read the announcement
Videos
Press Releases
SafeHeal® Closes Oversubscribed €35 Million Series C Equity Financing
Breakthrough device promises significantly improved patient recovery after colorectal surgery.
Read MoreSafeHeal Receives Breakthrough Device designation for Colovac Endoluminal Bypass Sheath
Breakthrough device promises significantly improved patient recovery after colorectal surgery.
Read More
Chief Executive Officer Chris Richardson to Speak at LSI Emerging Medtech Summit
Chris Richardson, CEO of SafeHeal, will be presenting an overview of the...
Read MoreSafeHeal appoints medical device industry veteran Chris Richardson as Chief Executive Officer
Breakthrough device promises significantly improved patient recovery after colorectal surgery.
Read MoreSafeHeal Completes First-in-Human Clinical Study of Endoluminal Bypass Sheath
SafeHeal, an innovator in the field of digestive surgery, has concluded its...
Read MoreSAFEHEAL starts first-in-human and CE-mark clinical study of endoluminal bypass sheath with the potential of replacing ostomy
The study will evaluate safety and efficacy of the Colovac bypass device...
Read More1 Colovac is an investigational device limited by Federal (United States) law to investigational use. In the European Union, Colovac is exclusively used for clinical investigations. The Colovac device has not yet received regulatory approval, therefore the potential risks and benefits are not yet established.
V10.1_06162025